Selected Publications

Academic Article

Year Title Altmetric
2019 ApoE-associated modulation of neuroprotection from Aβ-mediated neurodegeneration in transgenic Caenorhabditis elegans.Disease Models & Mechanisms2019
2018 Distinct functional roles of Vps41-mediated neuroprotection in Alzheimer's and Parkinson's disease models of neurodegeneration.Human Molecular Genetics.  27:4176-4193. 2018
2018 No Country for Old Worms: A Systematic Review of the Application of C. elegans to Investigate a Bacterial Source of Environmental Neurotoxicity in Parkinson's Disease.Metabolites.  8. 2018
2018 Correction to: The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity (Molecular Neurobiology, (2018), 55, 9, (7533-7552), 10.1007/s12035-018-0881-7)Molecular Neurobiology.  55:7553-7554. 2018
2018 The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity.Molecular Neurobiology.  55:7533-7552. 2018
2018 Gene-by-environment interactions that disrupt mitochondrial homeostasis cause neurodegeneration in C. elegans Parkinson's models.Cell Death and Disease.  9:555. 2018
2018 Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in S. cerevisiae and C. elegans models of Parkinson's disease.Human Molecular Genetics.  27:1514-1532. 2018
2017 Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in C. elegans Models of Parkinson's Disease.Journal of Neuroscience.  37:11085-11100. 2017
2017 Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration.Nature Neuroscience.  20:1560-1568. 2017
2017 Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans.ACS Chemical Neuroscience.  8:2596-2606. 2017
2017 NCEH-1 modulates cholesterol metabolism and protects against α-synuclein toxicity in a C. elegans model of Parkinson's disease.Human Molecular Genetics.  26:3823-3836. 2017
2017 Dihydropyrimidine-Thiones and Clioquinol Synergize To Target β-Amyloid Cellular Pathologies through a Metal-Dependent Mechanism.ACS Chemical Neuroscience.  8:2039-2055. 2017
2017 C. elegans as a model system to accelerate discovery for Parkinson disease.Current Opinion in Genetics and Development.  44:102-109. 2017
2017 Meet our editorial board memberCurrent Neuropharmacology.  15:195. 2017
2016 Chemical Compensation of Mitochondrial Phospholipid Depletion in Yeast and Animal Models of Parkinson's Disease.PLoS ONE.  11:e0164465. 2016
2015 A bacterial metabolite induces glutathione-tractable proteostatic damage, proteasomal disturbances, and PINK1-dependent autophagy in C. elegans.Cell Death and Disease.  6:e1908. 2015
2015 Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease.Human Molecular Genetics.  24:1322-1335. 2015
2015 Phenazine derivatives cause proteotoxicity and stress in C. elegans.Neuroscience Letters.  584:23-27. 2015
2014 RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway.Journal of Neuroscience.  34:16076-16085. 2014
2014 Phosphatidylethanolamine deficiency disrupts α-synuclein homeostasis in yeast and worm models of Parkinson disease.Proceedings of the National Academy of Sciences.  111:E3976-E3985. 2014
2014 Calcineurin determines toxic versus beneficial responses to α-synuclein.Proceedings of the National Academy of Sciences.  111:E3544-E3552. 2014
2014 The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models.Cell Metabolism.  20:145-157. 2014
2014 Clioquinol promotes the degradation of metal-dependent amyloid-β (Aβ) oligomers to restore endocytosis and ameliorate Aβ toxicity.Proceedings of the National Academy of Sciences.  111:4013-4018. 2014
2014 The effects of pdr1, djr1.1 and pink1 loss in manganese-induced toxicity and the role of α-synuclein in C. elegans.Metallomics.  6:476-490. 2014
2014 TorsinA rescues ER-associated stress and locomotive defects in C. elegans models of ALS.Disease Models & Mechanisms.  7:233-243. 2014
2014 Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.Cell.  156:170-182. 2014
2014 Protective role of DNJ-27/ERdj5 in Caenorhabditis elegans models of human neurodegenerative diseases.Antioxidants and Redox Signaling.  20:217-235. 2014
2014 Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C. elegans Parkinson's model.Cell Death and Disease.  5:e984. 2014
2013 Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons.Science.  342:979-983. 2013
2013 Lysosomal impairment in Parkinson's disease.Movement Disorders.  28:725-732. 2013
2013 Valproic acid ameliorates C. elegans dopaminergic neurodegeneration with implications for ERK-MAPK signaling.Neuroscience Letters.  541:116-119. 2013
2013 Invertebrate models of dystoniaCurrent Neuropharmacology.  11:16-29. 2013
2012 Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.Human Molecular Genetics.  21:3785-3794. 2012
2012 A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.Neurotherapeutics.  9:393-404. 2012
2012 The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress responseHuman Molecular Genetics.  21:1201. 2012
2012 Functional analysis of VPS41-mediated neuroprotection in Caenorhabditis elegans and mammalian models of Parkinson's disease.Journal of Neuroscience.  32:2142-2153. 2012
2012 Different 8-hydroxyquinolines protect models of TDP-43 protein, α-synuclein, and polyglutamine proteotoxicity through distinct mechanisms.Journal of Biological Chemistry.  287:4107-4120. 2012
2011 Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeastScience.  334:1241-1245. 2011
2011 Methodological strategies to evaluate functional effectors related to parkinson's disease through application of caenorhabditis elegans modelsNeuromethods.  61:31-53. 2011
2011 Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.Human Molecular Genetics.  20:3933-3942. 2011
2011 TorsinA participates in endoplasmic reticulum-associated degradation.Nature Communications.  2:393. 2011
2011 Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.Cell.  146:37-52. 2011
2011 Cell culture to investigate neurotoxicity and neurodegeneration utilizing Caenorhabditis elegansNeuromethods.  56:129-143. 2011
2011 Caenorhabditis elegans as a model system for identifying effectors of α-synuclein misfolding and dopaminergic cell death associated with Parkinson's disease.Methods.  53:220-225. 2011
2011 Modeling dopamine neuron degeneration in Caenorhabditis elegans.Methods in Molecular Biology.  793:129-148. 2011
2010 The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response.Human Molecular Genetics.  19:3502-3515. 2010
2010 The early-onset torsion dystonia-associated protein, torsinA, displays molecular chaperone activity in vitro.Cell Stress and Chaperones.  15:605-617. 2010
2010 Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction.Journal of Neurochemistry.  114:1193-1204. 2010
2010 Disinfecting dystonia? Drug discovery using worms identifies an antibiotic as a neuroprotective lead molecule for movement disordersFuture Neurology.  5:473-476. 2010
2010 C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease.Developmental Dynamics.  239:1282-1295. 2010
2010 Chemical enhancement of torsinA function in cell and animal models of torsion dystonia.Disease Models & Mechanisms.  3:386-396. 2010
2010 Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models.Disease Models & Mechanisms.  3:194-208. 2010
2010 VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease.Neurobiology of Disease.  37:330-338. 2010
2010 Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease.Cell Death and Disease.  1:e2. 2010
2009 Pharmacogenetic analysis reveals a post-developmental role for Rac GTPases in Caenorhabditis elegans GABAergic neurotransmission.Genetics.  183:1357-1372. 2009
2009 Investigating bacterial sources of toxicity as an environmental contributor to dopaminergic neurodegeneration.PLoS ONE.  4:e7227. 2009
2009 Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models.Nature Chemical Biology.  5:655-663. 2009
2009 Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.Nature Genetics.  41:308-315. 2009
2009 The microtubule-associated protein, NUD-1, exhibits chaperone activity in vitro.Cell Stress and Chaperones.  14:95-103. 2009
2008 Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.Molecular Brain.  1:17. 2008
2008 Paradigms for pharmacological characterization of C. elegans synaptic transmission mutants.Journal of Visualized Experiments2008
2008 Generation of stable transgenic C. elegans using microinjection.Journal of Visualized Experiments2008
2008 Application of a C. elegans dopamine neuron degeneration assay for the validation of potential Parkinson's disease genes.Journal of Visualized Experiments2008
2008 Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.Neuroscience Letters.  439:129-133. 2008
2008 Traversing a wormhole to combat Parkinson's disease.Disease Models & Mechanisms.  1:32-36. 2008
2008 Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model.Proceedings of the National Academy of Sciences.  105:728-733. 2008
2008 The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis.Proceedings of the National Academy of Sciences.  105:145-150. 2008
2008 Animal models for drug discovery in dystoniaExpert Opinion on Drug Discovery.  3:83-97. 2008
2007 Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation.BMC Cell Biology.  8:32. 2007
2006 Genetic interactions among cortical malformation genes that influence susceptibility to convulsions in C. elegans.Brain Research.  1120:23-34. 2006
2006 Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models.Science.  313:324-328. 2006
2006 Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.Journal of Neuroscience.  26:6985-6996. 2006
2005 Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans.Journal of Neuroscience.  25:3801-3812. 2005
2004 MEC-2 is recruited to the putative mechanosensory complex in C. elegans touch receptor neurons through its stomatin-like domain.Current Biology.  14:1888-1896. 2004
2004 Epileptic-like convulsions associated with LIS-1 in the cytoskeletal control of neurotransmitter signaling in Caenorhabditis elegans.Human Molecular Genetics.  13:2043-2059. 2004
2004 An animal model to discern torsin function: suppression of protein aggregation in C. elegans.Advances in Neurology -New York- Raven Press-.  94:79-85. 2004
2004 Using Caenorhabditis elegans to probe toxicity of 1-alkyl-3-methylimidazolium chloride based ionic liquidsChemical Communications.  4:668-669. 2004
2003 Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis.Journal of Cell Science.  116:1991-2003. 2003
2003 Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins.Human Molecular Genetics.  12:307-319. 2003
2001 Evolutionarily conserved nuclear migration genes required for early embryonic development in Caenorhabditis elegans.Roux's archives of developmental biology : the official organ of the EDBO.  211:434-441. 2001
1996 Genetic interactions affecting touch sensitivity in Caenorhabditis elegans.Proceedings of the National Academy of Sciences.  93:6577-6582. 1996


Year Title Altmetric
2009 The nematode, Caenorhabditis elegans, as an emerging model for investigating epilepsy.  Ed. 40.  2009


Year Title Altmetric
2014 Use of Caenorhabditis elegans to Model Human Movement Disorders.  97-116. 2014
2005 Use of C. elegans to model human movement disorders.  111-126. 2005

Full Name

  • Guy Caldwell